Reliance Global Group (EZRA) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
8 May, 2026Executive summary
Focused on simplifying operations, strengthening the balance sheet, and establishing a framework for long-term growth, with an active execution phase and expansion into technology and life sciences through Scale51 and LifeSci Global Group.
Operates two segments: insurance/InsurTech platform for recurring revenue and strategic ventures (EZRA International, Scale51) for disciplined capital deployment in tech and life sciences.
Enhanced RELI Exchange platform and expanded direct-to-consumer reach with 5MinuteInsure.com, supporting organic growth and operational efficiency.
Strategic investments in post-quantum cybersecurity (Enquantum) and life sciences (LifeSci Global, Innervate Radiopharmaceuticals) using milestone-based, phased capital deployment.
Insurance platform provides stable cash flow, enabling selective investment in high-growth opportunities.
Financial highlights
Unrestricted cash increased to $2.3M from $1.3M sequentially; combined cash rose to $3.2M from $2.7M.
Working capital improved to $2.6M from $1.9M; stockholders' equity increased to $7.4M from $6.4M.
Commission income was $3.8M, down from $4.2M year-over-year due to divestitures, but retained businesses saw 11% organic revenue growth.
Net loss improved to $1.4M from $1.7M year-over-year, driven by lower operating and interest expenses.
Adjusted EBITDA was -$0.4M versus +$0.1M year-over-year, reflecting lower stock-based compensation add-backs.
Outlook and guidance
Plans to continue disciplined execution of the dual-segment model, broadening investment opportunities and advancing current holdings.
Expects further organic growth in insurance through technology enhancements and agent expansion.
Strategic ventures will focus on milestone-based capital deployment and selective acquisitions in tech and life sciences.
Management believes current liquidity and capital resources are sufficient for at least the next twelve months.
Reverse stock split aims to regain Nasdaq compliance; no assurance of sustained compliance.
Latest events from Reliance Global Group
- All proposals passed, with leadership focused on growth and stockholder value.EZRA
AGM 20266 May 2026 - Strategic tech expansion, divestitures, and improved financials position for future growth.EZRA
Q4 20256 May 2026 - Strategic investment in Innervate Radiopharmaceuticals advances late-stage healthcare platform exposure.EZRA
Proxy filing4 May 2026 - Annual meeting seeks approval for director elections, equity plan expansion, and major share issuance.EZRA
Proxy filing23 Mar 2026 - Shareholders will vote on director elections, equity plan expansion, and a $50M share issuance.EZRA
Proxy Filing12 Mar 2026 - Q2 net loss improved 62%, Spetner deal to double revenue and boost profitability.EZRA
Q2 20242 Feb 2026 - Raising $5.3M for growth, tech, and digital assets amid dilution and Nasdaq compliance risks.EZRA
Registration Filing23 Jan 2026 - Q3 2024 delivered revenue growth, cost cuts, positive Adjusted EBITDA, and major M&A and tech moves.EZRA
Q3 202415 Jan 2026 - Revenue up 2%, net loss down 24%, and tech advances set stage for further growth.EZRA
Q4 202426 Dec 2025